Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA® ▼ (lurasidone) at the 23rd European Congress of Psychiatry


News provided by

Sunovion Pharmaceuticals Europe Ltd

30 Mar, 2015, 12:51 GMT

Share this article

Share toX

Share this article

Share toX

VIENNA, March 30, 2015 /PRNewswire/ --

Sunovion Pharmaceuticals Europe Ltd. will present 10 new research posters on LATUDA® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, at the 23rd European Congress of Psychiatry (EPA).  The meeting will be held 28-31 March 2015 in Vienna, Austria.

"We are pleased to be presenting new data from clinical studies, including data and analyses from the schizophrenia and bipolar depression clinical trial programs, as part of our ongoing commitment to increasing understanding of LATUDA among the European psychiatric research community," said Antony Loebel, M.D., Executive Vice President and Chief Medical Officer, Sunovion Pharmaceuticals Inc.

Following is a summary of the LATUDA presentations sponsored by Sunovion:

•    1139: Effects of Lurasidone on Hostility in Patients with an Acute Exacerbation of Schizophrenia: A Pooled Post-Hoc Analysis of 5 Short-Term Studies (Oral Presentation on Tuesday 31 March from 15:27-15:36 in Hall L8) 

     o    Authors: Leslie Citrome, M.D., Ph.D., Andrei Pikalov, M.D., Ph.D., Michael Tocco, Ph.D., Jay Hsu, Ph.D., Antony Loebel, M.D.

•    0830: Efficacy and Safety of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-Label Study (ePoster) 

     o    Authors: Brent Forester, M.D., Martha Sajatovic, M.D., Joyce Tsai, Ph.D., Hans Kroger, M.P.H., Andrei Pikalov, M.D., Ph.D., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D.

•    0834: Efficacy and Safety of Lurasidone in Older Adults with Bipolar Depression: Analysis of Two Double-Blind, Placebo-Controlled Studies (ePoster) 

     o    Authors: Martha Sajatovic, M.D., Brent Forester, M.D., MSc., Joyce Tsai, Ph.D., Hans Kroger, M.P.H., Andrei Pikalov, M.D., Ph.D, Josephine Cucchiaro, Ph.D., Antony Loebel, M.D.

•    0905: Cost-Utility Analysis of Lurasidone versus Aripiprazole in Adults with Schizophrenia in Scotland (ePoster) 

     o    Authors: Krithika Rajagopalan, Ph.D., Francesca L. Crowe, Ph.D., David Trueman, MSc., Andrei Pikalov, M.D., Ph.D., Antony Loebel, M.D.

•    0920: Effect of Lurasidone on Metabolic Parameters in Patients with Bipolar Depression (ePoster) 

     o    Authors: John Newcomer, M.D., Joyce Tsai, Ph.D., Andrei Pikalov, M.D., Ph.D., Hans Kroger, M.P.H., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D.

•    0923: Optimizing Treatment with Lurasidone in Patients with Schizophrenia: Results of a Randomized, Double-Blind, Placebo-Controlled Study (ePoster) 

     o    Authors: Antony Loebel, M.D., Robert Silva, Ph.D., Robert Goldman, M.D., Kei Watabe, M.S., Andrei Pikalov, M.D., Ph.D., Josephine Cucchiaro, Ph.D., John M. Kane, M.D.

•    1006: Symptomatic and Functional Remission and Recovery in Lurasidone-Treated Patients with Bipolar I Depression (ePoster) 

     o    Authors: Antony Loebel, M.D., Cynthia O. Siu, Ph.D., Krithika Rajagopalan, Ph.D., Andrei Pikalov, M.D., Ph.D., Josephine Cucchiaro, Ph.D., Terence A. Ketter, M.D.

•    1111: Pharmacokinetic and Safety Evaluation of Lurasidone in Pediatric Patients with Psychiatric Disorders (ePoster) 

     o    Authors: Robert Findling, M.D., M.B.A., Yu-Yuan Chiu, Ph.D., Robert Silva, Ph.D., Robert Goldman, Ph.D., Fengbin Jin, Ph.D., Andrei Pikalov, M.D., Ph.D., Antony Loebel, M.D.

•    1721: Lurasidone and Sexual Dysfunction: Post-Hoc Analysis of Pooled Data (ePoster) 

     o    Authors: Rodrigo Palma dos Reis, M.D., Henrik Andersson, MSc., Venkatesh Murthy, M.D., Ph.D.

•    1723: Long-Term Lurasidone Treatment is Not Associated with Clinically Significant Increases in Prolactin- or Hyperprolactinaemia-Related Adverse Events: A Post-Hoc Analysis (ePoster) 

     o    Authors: Amir Inamdar, MBBS, Boadie W. Dunlop, M.D., Rodrigo Palma dos Reis, M.D., Henrik Andersson, MSc., Venkatesh Murthy, M.D., Ph.D.

The marketing authorisation for LATUDA in the EU was based on short- and long-term data, which found LATUDA to be effective in treating adult patients with schizophrenia.[1],[2],[3],[4],[5],[6],[7]  LATUDA is not indicated in the EU for the treatment of bipolar depression.  

This medicine is subject to additional monitoring.  This will allow quick identification of new safety information. You can help by reporting any side effects.  See http://www.mhra.gov.uk/yellowcard for how to report side effects.  Please find links to the LATUDA Summary of Product Characteristics (SmPC) and the Prescribing Information at http://www.medicines.org.uk/emc/medicine/29125 and http://latuda.co.uk/prescribing-information/.  

NOTES TO EDITORS: 

In the UK the Commission on Human Medicines (CHM) and the Medicines and Healthcare Products Regulatory Agency (MHRA) encourage the reporting of all suspected adverse reactions (side effects) to newer drugs and vaccines, which are denoted by an inverted, equilateral black triangle (▼). LATUDA carries a black triangle to denote additional monitoring is required in relation to adverse reactions. You can help by reporting any side effects you may get. See http://www.mhra.gov.uk/yellowcard for how to report side effects. Please find links to the LATUDA Summary of Product Characteristics (SmPC) and the Prescribing Information at http://www.medicines.org.uk/emc/medicine/29125 and http://latuda.co.uk/prescribing-information/.  

About LATUDA® (lurasidone) 

LATUDA is an atypical antipsychotic, developed originally by Sumitomo Dainippon Pharma Co., Ltd. It has high affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors (full antagonist).[10]  In addition, LATUDA is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine (H1) or muscarinic (M1) receptors.[3]

The recommended starting dose of LATUDA is 37 mg once-daily with a meal.  No initial dose titration is required. It is effective in a dose range of 37-148 mg once-daily.[8]

LATUDA was approved for the treatment of schizophrenia in adults in the US in October 2010, in Canada in June 2012, in Switzerland in August 2013, in Australia in March 2014 and in the EU in March 2014.  LATUDA is available in Switzerland, Norway, Finland, the Netherlands and the UK.  Outside of Europe, LATUDA is available in the US and Canada.

For more information about LATUDA, please visit http://www.latuda.co.uk.

About Schizophrenia 

Schizophrenia is a severe, chronic mental condition that can affect both men and women.[9]  Patients with schizophrenia have a life span that is decreased by approximately 10-22.5 years compared with the general population.[10],[11]

Antipsychotic pharmacotherapy is the cornerstone of treatment for patients with schizophrenia, with agents classified as typical or atypical.  Atypical agents are broadly considered to have tolerability benefits over typical agents.[12]  Switching antipsychotic medication is common in the treatment of patients with schizophrenia either due to residual or emergent symptoms, adverse events or tolerability issues.[13]

Direct and indirect costs associated with caring for patients with schizophrenia are considerable and can include utilisation of other health services, pharmacotherapy, community care, supportive therapy, informal care and private expenditures, and patient and caregiver lost productivity.[14],[ 15]  Hospitalisation associated with patient relapse significantly increases costs associated with disease management in schizophrenia.[16]

About Sunovion Pharmaceuticals Europe Ltd. 

Sunovion Pharmaceuticals Europe, headquartered in London, UK, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc.  Additional information about Sunovion Europe is available at http://www.sunovion.eu.

Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.  Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercialising therapeutic products that advance the science of medicine and improve the lives of patients and their families.  

About Sumitomo Dainippon Pharma Co., Ltd.    

Sumitomo Dainippon Pharma is a top-ten listed pharmaceutical company in Japan.  Sumitomo Dainippon Pharma aims to produce innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas.  Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd.  Today, Sumitomo Dainippon Pharma has about 7,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at http://www.ds-pharma.com.

LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a US subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

© 2015 Sunovion Pharmaceuticals Inc.  

For a copy of this release, visit the Sunovion web site at http://www.sunovion.com

References  

1.    Meltzer H et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011; 168:957-67

2.    Loebel A et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013; 145:101-109

3.    Nakamura M et al. Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry 2009;70:829-36

4.    Ogasa M et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacol [Berl] 2013;225(3):519-30

5.    Loebel A et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, non-inferiority study. Schizophr Res. 2013; (147) 95-102

6.    Nasrallah H.A., et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomised, placebo-controlled study. J Psych Res 2013; 47:670-677

7.    Stahl, S.M., et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open- label, extension study. J Clin Psychiatry 2013

8.    Latuda. Summary of Product Characteristics. 2014

9.    National Institute of Mental Health. What is Schizophrenia? Available at: http://www.nimh.nih.gov/health/publications/schizophrenia/index.shtml Last accessed: July 2014

10.    Healy D et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010BMJ Open 2012;2:e001810

11.    Tiihonen J et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7

12.    Lewis DA and Lieberman JA. Catching up on schizophrenia: Review natural history and neurobiology. Neuron 2000;28:325-34

13.    Faries DE et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia BMC Psych 2009;9:54

14.    Salize HJ et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res 2009;111(1-3):70-7

15.    Mangalore R and Knapp R. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10(1):23-41

16.    Zeidler J et al. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective Health Econ Rev 2012;2(1):9

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.